Background: Anti-transcriptional intermediary factor 1 gamma (anti-TIF1γ) is an autoantibody that has gained increasing recognition as a paraneoplastic marker expressed in patients with dermatomyositis and occult malignancy. Its presence in patients without dermatomyositis but occult malignancy is less well established. The management of synchronous malignancies, such as concurrent lymphoproliferative and solid tumor neoplasms in patients also remains a major therapeutic challenge. Case Description: A female in her 60s presented with persistent weakness and systemic illness was found to have anti-TIF1γ antibodies during work-up for suspected myositis. Ultimately, the patient did not meet diagnostic criteria for an inflammatory myositis. However, recognizing the association between anti-TIF1γ with malignancy prompted a work-up that identified synchronous aggressive Epstein-Barr virus-positive marginal zone lymphoma (MZL) and stage IIA colon adenocarcinoma. While remission of her MZL was achieved with bendamustine-rituximab, her metastatic colonic adenocarcinoma was therapy-resistant in the setting of KRASG12D mutation, resulting in decision to transition her to palliative care after failed response to multiple chemotherapy regimens. Conclusions: This case details the clinical relevance of anti-TIF1γ as a rare but clinically important marker of immune dysregulation while highlighting the diagnostic and therapeutic challenges of managing a patient with aggressive, synchronous primary malignancies.
No takes yet. Share an insight, caveat, or question.
Robertson et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: